Fireside Chat: Navigating the evolving funding landscape for capital-intensive CGTs

Raising capital for cell and gene therapies presents unique challenges, from high manufacturing costs to long development timelines. In this fireside chat, leaders examine how investors and companies can navigate shifting markets, structure deals, and ensure the viability of transformative therapies. 

Key takeaways: 

• Assess the current funding climate for capital-intensive therapies 

• Explore models for de-risking investment and improving ROI 

• Adapt financing strategies to evolving investor priorities 

• Balance long-term R&D commitments with near-term capital needs 

• Apply lessons from recent deal structures and funding rounds